To assess the potential
cytostatic properties of Pt(II) complexes with
3-hydroxymethylpyridine (3-hmpy) as the only carrier
ligand, novel cis-[PtCl2(3-hmpy)2] (1) and trans-[PtCl2(3-hmpy)2] (2) have been prepared. Elemental analysis, FTIR spectroscopy, multinuclear NMR spectroscopy and X-ray crystallography were used to determine their structures. Based on the results obtained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) assay and clonogenic assay on T24 human bladder
carcinoma cells (T24), the most potent compound 2 was further tested for cytotoxicity in human ovarian
carcinoma cell lines -
cisplatin sensitive (IGROV 1) and its resistant subclone (IGROV 1/RDDP). The cytotoxicity of compound 2 in IGROV 1/RDDP is comparable to
cisplatin. Furthermore, compound 2 induced severe conformational changes in plasmid
DNA, which resulted in a delayed onset of apoptosis in T24 cells, and higher amounts of Pt in tumours and serum compared to
cisplatin. In addition, in vivo antitumour effectiveness was comparable to that of
cisplatin with a smaller reduction of animals'
body weight, thus demonstrating that it is a promising
transplatin analogue which deserves further studies.